Literature DB >> 2166605

Detection and isolation of the erythropoietin receptor using biotinylated erythropoietin.

A W Wognum1, P M Lansdorp, R K Humphries, G Krystal.   

Abstract

Procedures have been developed to label human erythropoietin (Ep) with biotin to detect and isolate the Ep-receptor. The labeling method used the abundant carbohydrate groups on Ep and resulted in biologically active biotin-Ep (b-Ep) containing 8 to 10 biotins per Ep molecule. Specific binding of b-Ep to cells from spleens of mice made anemic by phenylhydrazine injections was demonstrated using 125I-labeled streptavidin. B-Ep, together with fluorescently tagged streptavidin, was found to specifically detect Ep-receptor-bearing cells by flow cytometry. This was demonstrated in several ways. First, approximately 90% of nucleated spleen cells from phenylhydrazine-treated mice were clearly fluorescent after staining with b-Ep and streptavidin-phycoerythrin, whereas only background fluorescence was detected using spleen cells from untreated mice. In addition, Ep-receptors were detected on 5% to 10% of normal mouse bone marrow cells, and these cells could be identified as erythroid in nature by separating the cells into subpopulations based on light-scatter properties. Third, Ep-receptor expression was found to correlate positively with expression of transferrin receptors, confirming the erythroid nature of these cells. B-Ep was also used to isolate Ep-receptors from monkey COS cells transfected with the murine Ep-receptor cDNA. In these experiments a cell-surface-bound protein of approximately 65 Kd and an intracellular protein of approximately 60 Kd were isolated from these cells. The procedures described in this report for detecting Ep-receptor expressing cells and for isolating the Ep-receptor should be valuable for purifying erythroid cells from heterogeneous cell populations, for elucidating the structure of the Ep-receptor, and for studying the biological activities of Ep at the cellular and molecular level.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2166605

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc.

Authors:  L Liu; J E Damen; R L Cutler; G Krystal
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

2.  Inhibition of in vitro erythropoiesis by soluble mediators in Plasmodium chabaudi AS malaria: lack of a major role for interleukin 1, tumor necrosis factor alpha, and gamma interferon.

Authors:  G S Yap; M M Stevenson
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

3.  Homodimerization and constitutive activation of the erythropoietin receptor.

Authors:  S S Watowich; A Yoshimura; G D Longmore; D J Hilton; Y Yoshimura; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

4.  In vitro phosphorylation of the erythropoietin receptor and an associated protein, pp130.

Authors:  A Yoshimura; H F Lodish
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

5.  Erythropoietin down-regulates stem cell factor receptor (Kit) expression in the leukemic proerythroblast: role of Lyn kinase.

Authors:  Olivier Kosmider; Dorothée Buet; Isabelle Gallais; Nicole Denis; Françoise Moreau-Gachelin
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

6.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27

7.  Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation.

Authors:  J E Damen; H Wakao; A Miyajima; J Krosl; R K Humphries; R L Cutler; G Krystal
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

8.  Epo receptors are not detectable in primary human tumor tissue samples.

Authors:  Steve Elliott; Susan Swift; Leigh Busse; Sheila Scully; Gwyneth Van; John Rossi; Carol Johnson
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.